论文部分内容阅读
经过十多年的改革开放,我国小型制药企业发展迅速。但随着计划经济向市场经济的转轨,绝大部分小型制药企业“功底”逐步显露,有的力不从心,有的在“十字路口”徘徊不定,形势令人担忧。小型制药企业是医药业主要成员之一,不但比例大,而且分布广、人数多,对经济,特别是地方经济起着重要作用。面对当今竞争激烈的医药市场,小型制药企业何处去,是医药行业不可回避的现实问题。一、现状与原因到1992年底止,我国小型制药企业占全部制药企业2141家的76%以上。就每个企业平均而言,职工人数一般都在300人左右;固定资产净值绝大部分在400万元以下,其中,
After more than a decade of reform and opening up, China’s small pharmaceutical companies have developed rapidly. However, with the transition from a planned economy to a market economy, the vast majority of small-scale pharmaceutical companies have gradually exposed their “money,” and some have been unable to do so, and some have become uncertain at a “crossroads,” and the situation is worrying. Small pharmaceutical companies are one of the major members of the pharmaceutical industry. They not only have a large proportion, but also have a wide distribution and a large number of people. They play an important role in the economy, especially in the local economy. In the face of today’s highly competitive pharmaceutical market, where small pharmaceutical companies go is an unavoidable reality in the pharmaceutical industry. I. Status Quo and Reasons By the end of 1992, China’s small pharmaceutical companies accounted for more than 76% of 2,141 pharmaceutical companies. On average, the average number of workers is about 300. The net value of fixed assets is less than 4 million yuan. Among them,